Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

436264

registered interest
date	08/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether he plan to respond to the Accelerated Access Review: Interim Report, published in October 2015; and if he will make a statement.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	19241
answer	answer is ministerial correction date of answer 15/12/2015 answer text <br /><p>The Interim Report of Sir Hugh Taylor’s Accelerated Access Review (AAR) is a deliberately high level document that indicates direction of travel; as such, government will be responding to the AAR’s conclusions when its final recommendations are published early in the spring of 2016.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/12/2015 16:30:10 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

436265

registered interest
date	08/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Leukaemia: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will ensure that the new Cancer Drugs Fund will increase patient access to medicines for acute myeloid leukaemia.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	19240
answer	answer is ministerial correction date of answer 15/12/2015 answer text <p>NHS England and the National Institute for Health and Care Excellence are currently consulting jointly on draft proposals on the future direction of the Cancer Drugs Fund.</p><br /><p>The consultation was published on 19 November 2015 and is open until 11 February 2016. It states that it is looking to put in place a solution that ensures patients have routine access to a greater range of cancer drugs, including earlier access to innovative drugs, while ensuring that cost-effectiveness is maintained. Further information is available at:</p><p>www.engage.england.nhs.uk/consultation/cdf-consultation</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/12/2015 16:22:51 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

434007

registered interest
date	03/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Myeloma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that the treatment of patients with multiple myeloma is not affected by the (a) delisting of treatments from the Cancer Drugs Fund and (b) ongoing consultation on that Fund's future.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	18734
answer	answer is ministerial correction date of answer 10/12/2015 answer text <p>NHS England has advised that a draft treatment pathway for patients with multiple myeloma, which takes into account the potential impact of treatments removed from the Cancer Drugs Fund (CDF), is currently being finalised. It is likely to be published early in 2016.</p><br /><p>The Government remains committed to the Fund. NHS England and the National Institute for Health and Care Excellence are currently consulting on draft proposals on the future direction of the CDF. The consultation is open until 11 February 2016 and further information is available at:</p><br /><p>www.engage.england.nhs.uk/consultation/cdf-consultation</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/12/2015 14:17:08 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

434008

registered interest
date	03/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure the outcome of the consultation on the future of the Cancer Drugs Fund is co-ordinated with and complements the recommendations of the Accelerated Access Review to ensure improved patient access to innovative treatments.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	18766
answer	answer is ministerial correction date of answer 10/12/2015 answer text <p>NHS England and the National Institute for Health and Care Excellence are currently consulting on draft proposals on the future direction of the Cancer Drugs Fund (CDF). The consultation is open until 11 February 2016 and further information is available at:</p><br /><p>www.engage.england.nhs.uk/consultation/cdf-consultation</p><br /><p>The Accelerated Access Review independently chaired by Sir Hugh Taylor, is working with key stakeholders on a range of options for accelerating patient access to innovative products, as set out in the interim report. This includes consideration of the impact of managed access schemes such as proposed in the CDF consultation.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 10/12/2015 14:04:50 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

428358

registered interest
date	16/11/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to improve the assessment of medicines for rarer cancers with small patient populations.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	16497
answer	answer is ministerial correction date of answer 23/11/2015 answer text <p>NHS England has advised that it intends to jointly consult with the National Institute for Health and Care Excellence on proposals for a new Cancer Drugs Fund operating model. This will include the future arrangements for the evaluation of cancer drugs, including drugs for rarer cancers with small patient populations. Members of the public and any interested parties will have the opportunity to consider and comment on these proposals.</p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 16188 question first answered 23/11/2015 10:58:14 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

226307

registered interest
date	10/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 24 February 2015 to Question 223768, on which dates since 24 November 2014 he has discussed with NHS England its revised approach to promoting and taking account of research in the new healthcare system; and what the content of those discussions was.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	227007
answer	answer is ministerial correction date of answer 17/03/2015 answer text <p>Since 24 November 2014, there have been no discussions between my Rt. Hon. Friend the Secretary of State for Health and NHS England on its revised approach to promoting and taking account of research in the new healthcare system. However, discussions between senior officials in the Department and NHS England are ongoing.</p><p> </p><p> </p><p> </p><p>NHS England will be setting out high level plans through their Business Plan, which is due to be published on 27 March 2015. NHS England does not routinely consult on business plans and, as such, no formal consultation has been planned.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 227008 question first answered 17/03/2015 16:19:17 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

226308

registered interest
date	10/03/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 24 February 2015 to Question 223768, when NHS England plans to publish its revised approach to promoting and taking account of research in the new healthcare system; and what plans NHS England has to hold a formal consultation on that revised approach.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	227008
answer	answer is ministerial correction date of answer 17/03/2015 answer text <p>Since 24 November 2014, there have been no discussions between my Rt. Hon. Friend the Secretary of State for Health and NHS England on its revised approach to promoting and taking account of research in the new healthcare system. However, discussions between senior officials in the Department and NHS England are ongoing.</p><p> </p><p> </p><p> </p><p>NHS England will be setting out high level plans through their Business Plan, which is due to be published on 27 March 2015. NHS England does not routinely consult on business plans and, as such, no formal consultation has been planned.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 227007 question first answered 17/03/2015 16:19:16 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

178540

registered interest
date	09/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects to publish the results of the consultation for the NHS England Research and Development Strategy.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	223768
answer	answer is ministerial correction date of answer 24/02/2015 answer text <p>The consultation for the NHS England Research and Development Strategy closed in December 2013. NHS England subsequently decided not to publish the results of the consultation at that time, but instead to use the findings to inform a new piece of work which would be developed with the Department which will describe NHS England’s role in promoting and taking account of research in the new healthcare system.</p><p> </p><p> </p><p> </p><p>NHS England is working with the Department to agree a revised approach.</p><p> </p><p> </p><p> </p><p>Delivery of NHS England’s research objective was discussed at the accountability meeting on 14 October 2014. The minutes of this meeting are available at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/377477/SofS_Accountability_Meeting_oct_2014.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/377477/SofS_Accountability_Meeting_oct_2014.pdf</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/02/2015 16:49:23 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

174759

registered interest
date	20/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Bile Duct Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what research his Department has commissioned into cholangiocarcinoma.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	221396
answer	answer is ministerial correction date of answer 27/01/2015 answer text <p>The Department has not commissioned any research relating specifically to cholangiocarcinoma. The National Institute for Health Research Imperial Biomedical Research Centre has a £3.6 million gastroenterology and hepatology research theme (2012-17). This includes research on cholangiocarcinoma biomarkers and imaging.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/01/2015 12:35:01 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith

155948

registered interest
date	17/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to encourage flexibility in the licensing process for potential new treatments for rare conditions.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	214491
answer	answer is ministerial correction date of answer 24/11/2014 answer text <p>Most new medicines for rare conditions are licensed by the European Commission.</p><p> </p><p>The European Union offers a range of incentives to encourage the development of these medicines in order to address unmet clinical need. These incentives include a period of 10 years market exclusivity, the provision of Protocol Assistance (scientific advice specifically tailored for orphan medicinal products) and fee reductions and waivers for regulatory procedures.</p><p> </p><p> </p><p> </p><p>Through the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom takes an active role in the decision making process at the European Medicines Agency’s Committee on Orphan Medicinal Products, ensuring applications for Orphan Drug designation of potential drug candidates for rare diseases are appropriately recognised, encouraging companies to develop their products further and recommending use of existing flexibilities such as conditional authorisation, authorisation under exceptional circumstances and accelerated assessment. The UK is actively involved in the European Medicines Agency’s adaptive licensing pilot that is exploring further use of these flexibilities. The MHRA has an Innovation Office that can offer advice and assistance to developers of drugs for rare diseases, including on the use of flexibilities.</p><p> </p><p><strong> </strong></p><p> </p><p>In addition, in the UK, the Early Access to Medicines Scheme aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2014 17:23:13 answering member 4020 label Biography information for George Freeman
tabling member	3960 label Biography information for Henry Smith